## (19) World Intellectual Property Organization

International Bureau



## 

(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

## (10) International Publication Number WO 2004/087138 A1

(51) International Patent Classification<sup>7</sup>: A6
A61P 27/00, 17/00, 11/00

A61K 31/426,

(21) International Application Number:

PCT/JP2004/004596

- (22) International Filing Date: 31 March 2004 (31.03.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/458,370

31 March 2003 (31.03.2003) U

- (71) Applicants (for all designated States except US): SU-CAMPO AG [CH/CH]; Graben 5, Zug, CH-6300 (CH). FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP).
- (72) Inventors; and
- [JP/US]; 11025 Stanmore Drive, Potomac, Montgomery, MD 20854 (US). NAGASHIMA, Akira [JP/JP]; c/o FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP). INOUE, Takayuki [JP/JP]; c/o FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP). OHKUBO, Mitsuru [JP/JP]; c/o FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP). YOSHIHARA, Kousei [JP/JP]; c/o FUJISAWA PHARMACEUTICAL

CO., LTD., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5418514 (JP).

- (74) Agent: TAKASHIMA, Hajime; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE

(57) Abstract: The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. The agents are 2-acylamino thiazole compounds.

WO 200